With direct injection into the target tissue, there are multiple potential advantages to this method, including lower systemic toxic side effects, direct delivery of RNA therapy, higher retention of cell therapy. All of which are potential advantages to systemic infusion.
INVENTORS AT KAROLINSKA
Staffan Holmin, MD, PhD is a Professor in Clinical Neuroimaging in the department of Clinical Neuroscience, Karolinska Institutet and Senior physician/Consultant in endovascular neurointerventional procedures in the department of Neuroradiology, Karolinska University Hospital, as well as a research group leader who has published widely on novel neuroimaging and interventional techniques. In 2016, he gave the Seldinger Honorary Lecture at the European Congress of Radiology.
Johan Lundberg, MD, PhD is a resident in Neuroradiology at Karolinska University Hospital where he completed his medical and research training in the laboratory of Staffan Holmin. Dr. Lundberg has published extensively on methods of cell transplantation.
Stefan Jonsson, PhD is a Professor of Materials Science at KTH where he leads a research group studying high-temperature effects on engine materials as well as collaborating with Karolinska Hospital to study the effects of metals on endothelial cell retrieval methods.
Jonathan Clarke, MD is CEO of Smartwise and a Board Certified Cardiologist. He earned a medical degree at Harvard Medical School, where he was a Howard Hughes Medical Fellow, and completed his training in Internal Medicine at NYPH-Weil Cornell and Cardiology Fellowship at Massachusetts General Hospital in Boston. His research work in the laboratory of Ken Chien at Karolinska Institute has focused on novel cardiac stem cell and RNA therapies for heart disease.